Our data could have clinical implications because co-expression of EGFR and HER2 has been observed in 10% to 36% of primary human breast carcinomas, and it is generally associated with a poorer prognosis compared with breast carcinomas expressing a single receptor [45]. This evidence concerns the gene ERBB2 and breast carcinoma.